A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia.

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

The FDA has approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage over current treatments is milder side effects.

The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...